Dall’Era, Marc A.Cheng, LiangPan, Chong-Xian2025-06-262025-06-262012Dall'Era MA, Cheng L, Pan CX. Contemporary management of muscle-invasive bladder cancer. Expert Rev Anticancer Ther. 2012;12(7):941-950. doi:10.1586/era.12.60https://hdl.handle.net/1805/49009The current standard treatment for muscle-invasive nonmetastatic bladder cancer is neoadjuvant platinum-based chemotherapy followed by radical cystectomy. However, neoadjuvant chemotherapy is not widely accepted even with level 1 evidence. Adjuvant chemotherapy should be discussed if patients have not received neoadjuvant chemotherapy before surgery and have high-risk pathologic features. Although not considered standard of care, bladder-sparing therapy can be considered for highly selected patients and for those medically unfit for surgery. Even though there are no level 1 data, the treatment outcomes for highly select patients given bladder-sparing therapy appear promising, with many patients retaining a functional bladder. Personalized chemotherapy is currently being actively pursued to target the underlying molecular changes and tailor to individual needs.en-USPublisher PolicyBladder urothelial carcinomaChemotherapyCisplatinPersonalized chemotherapyTargeted therapyArticle